Skip to main content

FDA Updates

Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer

Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer

Xalkori Now FDA Approved for the Treatment of ALK-Positive Inflammatory Myofibroblastic Tumor

Breyanzi Now FDA Approved for Second-Line Treatment of Large B-Cell Lymphoma

Tafinlar plus Mekinist First Tumor Agnostic Therapy Approved for Any Unresectable or Metastatic Solid Tumors with BRAF Mutation

FDA Issues New Warning for Copiktra About Increased Risks for Serious Side Effects and Mortality

Talquetamab, First-in-Class Bispecific Monoclonal Antibody, Granted Breakthrough Therapy by the FDA for Relapsed or Refractory Multiple Myeloma

Tibsovo Received a New Indication, in Combination with Azacitidine, for Newly Diagnosed Patients with AML and IDH1 Mutation

Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma

Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer

4
5
6
7
8
9
10

Page 7 of 33
Results 61 - 70 of 330